Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Dicerna Pharmaceutic (DRNA)

Dicerna Pharmaceutic (DRNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,986,090
  • Shares Outstanding, K 78,129
  • Annual Sales, $ 164,310 K
  • Annual Income, $ -112,750 K
  • 60-Month Beta 0.80
  • Price/Sales 18.07
  • Price/Cash Flow N/A
  • Price/Book 27.59
Trade DRNA with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.63
  • Most Recent Earnings N/A on 11/09/21
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -0.44
  • Number of Estimates 4
  • High Estimate -0.04
  • Low Estimate -0.99
  • Prior Year -0.49
  • Growth Rate Est. (year over year) +10.20%

Price Performance

See More
Period Period Low Period High Performance
1-Month
37.78 +1.16%
on 12/10/21
38.26 -0.12%
on 12/03/21
+0.23 (+0.61%)
since 11/26/21
3-Month
19.06 +100.52%
on 10/06/21
38.26 -0.12%
on 12/03/21
+17.37 (+83.31%)
since 09/27/21
52-Week
19.06 +100.52%
on 10/06/21
40.14 -4.78%
on 07/20/21
+14.79 (+63.12%)
since 12/24/20

Most Recent Stories

More News
Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition

Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. (Dicerna; Nasdaq: DRNA), announced on 18 November 2021, has been completed.

DRNA : 38.22 (+0.58%)
Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Novo Nordisk’s...

DRNA : 38.22 (+0.58%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates COR, STXB, BCML, DRNA; Shareholders are Encouraged to Contact the Firm

NEW YORK, NY / ACCESSWIRE / November 23, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: CoreSite Realty Corporation (NYSE:COR) concerning...

COR : 219.94 (-0.46%)
STXB : 25.55 (-0.23%)
BCML : 23.47 (+1.25%)
DRNA : 38.22 (+0.58%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates DRNA, RRD, LEVL, HRC; Shareholders are Encouraged to Contact the Firm

NEW YORK, NY / ACCESSWIRE / November 22, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) concerning...

DRNA : 38.22 (+0.58%)
RRD : 10.84 (unch)
LEVL : 39.93 (-0.94%)
HRC : 155.96 (+0.03%)
Dicerna Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Dicerna Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – DRNA

Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) to Novo Nordisk for $38.25 per share in cash is fair to Dicerna shareholders....

DRNA : 38.22 (+0.58%)
Novo Nordisk to Acquire Dicerna

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that it has entered into a definitive agreement with Novo Nordisk under which Novo Nordisk will acquire Dicerna, a biopharmaceutical company...

DRNA : 38.22 (+0.58%)
Dicerna Announces Two Targets Meet Preclinical Proof of Principle Criteria in Neurodegeneration and Pain Under Global Research Collaboration and Licensing Agreement With Lilly

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Eli Lilly and Company (“Lilly”) has declared...

DRNA : 38.22 (+0.58%)
Dicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today presented results from its Phase 1 double-blind, placebo-controlled,...

DRNA : 38.22 (+0.58%)
Dicerna Announces Third Quarter 2021 Financial Results and Provides a Business Update

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported its financial results for the third quarter ended...

DRNA : 38.22 (+0.58%)
Dicerna Presents PHYOX™2 and Primary Hyperoxaluria Healthcare Utilization Data at American Society of Nephrology (ASN) Kidney Week 2021

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced results of the PHYOX™2 pivotal clinical trial...

DRNA : 38.22 (+0.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Dicerna Pharmaceuticals, Inc. is focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers. The company uses its proprietary RNA interference technology platform primarily in the United States and internationally. Dicerna Pharmaceuticals,...

See More

Key Turning Points

3rd Resistance Point 38.27
2nd Resistance Point 38.25
1st Resistance Point 38.24
Last Price 38.22
1st Support Level 38.21
2nd Support Level 38.19
3rd Support Level 38.18

See More

52-Week High 40.14
Last Price 38.22
Fibonacci 61.8% 32.09
Fibonacci 50% 29.60
Fibonacci 38.2% 27.11
52-Week Low 19.06

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar